Sanofi revenue 2025| ��ƽ��

Revenue of Sanofi from 2006 to 2025 (in million euros)

Characteristic	Revenue in million euros
2025	43,626
2024***	41,081
2023	43,070
2022	42,997
2021	37,761
2020	36,041
2019	36,126
2018	34,463
2017	35,072
2016**	33,809
2015	34,060
2014	31,380
2013	30,693
2012*	34,743
2011*	33,389
2010	32,367
2009	29,785
2008	27,568
2007	28,052
2006	28,373

Download

Source

Show detailed source information?

Already a member?

Sources

Release date

February 2026

More information

Region

Worldwide, France

Survey time period

2006 to 2025

Supplementary notes

Figures for 2006-2022 were quoted from previous annual reports.
* Including the Animal Health business, the net income/loss of which is presented in a separate line item. For 2012 and 2011, it is not practicable to provide information excluding the Animal Health business without unreasonable effort or expense.
** Due to a change in accounting presentation, VaxServe sales of non-Sanofi products are included in Other revenues from 2016 onwards. The presentation of prior period Net sales and Other revenues has been amended accordingly.

*** For 2024, the Consumer Healthcare segment (new name 'Opella') is already classified as a discontinued operation, and thus not included.

Citation formats

In 2025, Sanofi generated over 43 billion euros in revenue. The value was higher than in the previous two years due to the ongoing separation process of the consumer healthcare segment, which is already classified as a discontinued operation. Sanofi is a global leader in healthcare and pharmaceuticals based in Paris, France.

Sanofi’s company profile

Sanofi is one of the world’s leading pharmaceutical companies, and its subsidiaries include Genzyme and Sanofi Pasteur, to name a few. As of late 2026, Sanofi was no longer ranked among the top 10 global pharmaceutical companies based on market capitalization. However, the company is ranked among the top 10 global pharmaceutical companies based on its prescription sales.

Sanofi’s products and revenues

Sanofi works in several therapeutic sectors, including diabetes and cardiovascular diseases, oncology, immunology, multiple sclerosis, rare diseases, rare blood disorders, and vaccines. A majority of Sanofi’s revenues can be attributed to its pharmaceutical sector. Sanofi’s top pharmaceutical products, based on revenues, include Dupixent, Lantus, and Lovenox. Lantus is a long-acting insulin for use in type I and type II diabetes. Sanofi also used to have an animal health sector, but the business was sold to Boehringer Ingelheim in 2016.